Welcome to our dedicated page for ReShape Lifesciences SEC filings (Ticker: RSLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The RSLS SEC filings archive documents the regulatory history of ReShape Lifesciences Inc. prior to and through its transformation into Vyome Holdings, Inc. These filings, made with the U.S. Securities and Exchange Commission, provide detailed information on the company e2 80 99s weight loss and metabolic health device business, its major strategic transactions, and the subsequent name and ticker change to HIND on The Nasdaq Capital Market.
Key filings include multiple Form 8-K current reports describing material events. Among them are disclosures of the Agreement and Plan of Merger with Vyome Therapeutics, Inc., the closing of the merger on August 15, 2025, and the resulting change of the registrant e2 80 99s name to Vyome Holdings, Inc. They also describe the 1-for-4 reverse stock split of the company e2 80 99s common stock and the continuation of Nasdaq listing under the new trading symbol HIND. Other 8-K filings detail shareholder meeting results, including approvals of share issuances, the asset sale, charter amendments, and reverse split authorization.
The filings further outline the Asset Purchase Agreement with Ninjour Health International Limited, an affiliate of Biorad Medisys Pvt. Ltd., under which ReShape Lifesciences sold substantially all of its assets (excluding cash) and Biorad assumed substantially all of its liabilities. Disclosures specify that the Lap-Band ae System, Obalon ae Gastric Balloon System, and the DBSN ae system were among the assets transferred. Additional 8-K items address financing arrangements, such as an equity distribution agreement for at-the-market offerings, and changes in the company e2 80 99s independent registered public accounting firm.
After the merger, subsequent 8-K and 8-K/A filings under the Vyome Holdings, Inc. name (trading as HIND) provide Vyome e2 80 99s financial statements, management e2 80 99s discussion and analysis, and unaudited pro forma condensed combined financial statements giving effect to the merger. Amendments such as 8-K/A filings correct and update pro forma calculations, ensuring that the combined company e2 80 99s financial presentation is accurate for incorporation into existing shelf registration statements.
On Stock Titan, users can access these RSLS-related SEC filings in one place, with real-time updates pulled from EDGAR. AI-powered summaries help explain the significance of complex documents like 8-K merger reports, reverse stock split disclosures, and pro forma financial statements. Investors can also review historical ownership and governance changes, as reflected in board and executive transitions reported in the filings, and trace how the former ReShape Lifesciences entity evolved into Vyome Holdings, Inc. under the HIND ticker.
Vyome Holdings, Inc. is asking stockholders to approve four main items at its 2026 annual meeting on April 24 in New York. Investors will vote to re-elect Venkat Nelabhotla and John Tincoff as Class II directors, approve an advisory “say‑on‑pay” for named executive compensation, and ratify Kreit & Chiu CPA LLP as independent auditor for 2026.
A key proposal would amend the charter to cut authorized common stock from 300,000,000 to 50,000,000 shares. The board says this better matches capital needs, reduces potential dilution concerns and may lower Delaware franchise tax from about $155,000 to about $25,000 for tax years 2026 and 2027. As of March 2, 2026, 7,018,528 common shares were outstanding, with additional shares tied to options, plan reserves and warrants.
The proxy details board structure, committee roles—including a specialized AI Committee—beneficial ownership, and 2025 executive pay, including $478,711 in total compensation for CEO Venkat Nelabhotla. The board unanimously recommends voting FOR all proposals.
Vyome Holdings, Inc., through subsidiary Livechain, Inc. and its unit LICH Inc., entered a Notes Purchase and Exchange Agreement to acquire senior secured convertible notes of Humanyze with aggregate principal of $5,765,000 from Remus Capital.
As consideration, Livechain will issue 211,200,844 shares of its common stock to Remus, equal to 25% of Livechain’s fully diluted common stock immediately before closing, and reserve up to 84,480,338 additional shares (10%) for compensatory grants to key and future employees. After closing, substantially all Humanyze assets and operations are expected to be transferred to the buyer entity in satisfaction of the notes.
The agreement, a related party transaction, was approved by Vyome’s audit committee and board with interested Remus-affiliated directors recusing themselves, and the outside closing date was amended to March 8, 2026. A press release states the Livechain stock issued in the transaction is valued at approximately $325,000.
Vyome Holdings, Inc. furnished an investor presentation highlighting Phase 2 results for VT-1953, a 2% topical gel for malignant fungating wounds. In a 15-patient investigator-sponsored study, VT-1953 significantly reduced malodor by Day 14 versus baseline (p=0.0020) and versus vehicle (p=0.0015), and improved patient-reported malodor impact on quality of life (p=0.0256). Patients also showed statistically significant reductions in malodor and lesion pain on visual analog scales and better composite quality-of-life scores, while exudate did not materially change. VT-1953 was well tolerated with no treatment-emergent adverse events or local reactions reported. Vyome cites a U.S. market opportunity of about $2.2 billion based on ~58,000 new patients per year and a lifetime value per patient of $55,000, and states it is capitalized to fund operations until Phase 3 interim readouts.
Vyome Holdings, Inc. furnished an investor presentation and a related product assessment report about VT-1953, its lead clinical candidate for treating symptoms of malignant fungating wounds. These materials are provided as Exhibit 99.1 under Regulation FD and are not deemed filed for liability purposes.
The company also reported that it issued a press release on January 27, 2026, summarizing key findings from an independent U.S. market assessment, commercial forecast, and valuation analysis for VT-1953, which is attached as Exhibit 99.2. Both exhibits are incorporated by reference and include forward-looking statements about business strategy, capital needs, market potential, and future operating results.
Vyome Holdings Form 4: This Form 4 reports that Venkat Nelabhotla, President, CEO and a director, received 7 shares of Vyome Holdings common stock as a result of a merger on 08/15/2025. Under the Merger Agreement, each 5,000 shares of Vyome Therapeutics common stock converted into 1 share of Vyome Holdings common stock. The reporting person exchanged 35,000 Vyome Therapeutics shares and received 7 Vyome Holdings shares. The Form 4 was filed as a single reporting person and is signed on 09/22/2025.
John M. Tincoff III filed an initial Form 3 reporting his relationship to Vyome Holdings, Inc. (ticker shown in the filing as HIND) as a Director. The event date is 08/15/2025. The filing states no securities are beneficially owned by the reporting person. The form is signed and dated 09/18/2025.
Vyome Holdings, Inc. filed an amended Form 8-K to correct errors in previously filed pro forma financial information. The company states that Amendment No. 1 is being filed solely to replace Exhibit 99.3 with corrected Unaudited Pro Forma Condensed Combined Financial Statements, now provided as Exhibit 99.1.
No other disclosures from the original September 2, 2025 Form 8-K are modified, and the amendment does not address events occurring after that original filing date.
Robert Dickey IV, Chief Financial Officer and Director of Vyome Holdings, Inc., reported a change in beneficial ownership related to a merger involving Vyome Therapeutics. The reporting person received 762 shares of Vyome Holdings common stock on 08/15/2025 in exchange for 3,810,000 shares of Vyome Therapeutics common stock under the Merger Agreement, which converted every 5,000 Vyome Therapeutics shares into one share of the issuer. The Merger resulted in Vyome Therapeutics becoming a subsidiary of the issuer and the renamed parent company Vyome Holdings, Inc. The Form 4 discloses the acquisition as a non-derivative transaction and indicates the reporting person holds the shares directly.
Venkateswarlu Nelabhotla filed an SEC Form 3 reporting his initial statement of beneficial ownership with respect to Vyome Holdings, Inc. (ticker HIND). The filing, tied to an event dated 08/15/2025, identifies him as both President & CEO and a director. The Form 3 states no securities are beneficially owned by the reporting person. The form is signed and dated 09/11/2025.
Vyome Holdings, Inc. (ticker HIND) filed an Initial Statement of Beneficial Ownership (Form 3) for Robert Dickey IV, who is identified as the company’s Chief Financial Officer and a director. The filing reports the qualifying event date as 08/15/2025 and is signed on 09/11/2025. The form states explicitly that no securities are beneficially owned by the reporting person at the time of filing, meaning Mr. Dickey disclosed no direct or indirect ownership of the issuer’s equity or derivative securities in this submission.